Chemoradiation Therapy with Docetaxel/Fluorouracil/Nedaplatin for the Patients with Esophageal Cancer and Simultaneous Double Primary Malignancy
1Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School
2Department of Surgery, Nippon Medical School Tama Nagayama Hospital
3Department of Radiology, Nippon Medical School Tama Nagayama Hospital
To evaluate the efficacy and safety of chemoradiation therapy with docetaxel, fluorouracil, and nedaplatin for the patients with esophageal cancer and simultaneous double primary malignancy. Three patients with inoperable disease were enrolled to receive the combination of docetaxel 40 mg/m2 (on days 1 and 21), nedaplatin 10 mg/body (on days 1∼5 and 21∼25), and fluorouracil 350 mg/m2 (on days 1∼5 and 21∼25) with radiation (60 Gy in 2-Gy fractions over 6 weeks). Evaluated responses were a complete response in 1 patient and partial responses in 2 pateints. The overall response rate was 100%. Myelosuppressions with grade 2 leukopenia occurred in 2 patients (66%). This chemoradiation therapy is effective for and well-tolerable by patients with esophageal cancer and simultaneous double primary malignancy.
日医大医会誌 2008; 4(4), 197-200
double primary cancer, esophageal carcinoma, chemoradiation therapy
Takeshi Matsutani, MD, Department of Surgery, Nippon Medical School Tama Nagayama Hospital, 1-7-1 Nagayama, Tama, Tokyo 206-8512, Japan